文献速递前列腺增生与排尿功能障碍

骶神经调节治疗老年膀胱过度活动症:认知障碍是否影响疗效?一项前瞻性临床试验

Sacral Neuromodulation for Overactive Bladder in the Aging Population: Does Cognitive Impairment Impact Outcomes? A Prospective Clinical Trial.
PubMed 文献 · J Urol · 2025-07-30

该前瞻性试验纳入≥60岁难治性膀胱过度活动症(OAB)拟行骶神经调节(SNM)测试阶段的患者,以蒙特利尔认知评估<26/30定义认知障碍(CI)。

要点

  • 老年OAB行SNM者认知障碍发生率高(63%),但CI不影响测试阶段成功率。
  • CI组基线技术使用与信心较低,1个月时控制器适当使用率较低。
  • 短期患者报告结局在CI组与无CI组间无统计学差异。

核心结论

  • 老年OAB患者接受SNM时认知障碍发生率高,且与使用技术的舒适度降低相关,但无证据表明认知障碍影响SNM测试阶段成功或短期患者报告结局。

研究设计与样本

  • 前瞻性临床试验,招募≥60岁拟行测试阶段SNM的难治性OAB患者,共92例招募、88例接受测试阶段SNM(平均年龄73±8岁,89%女性)。
  • 以蒙特利尔认知评估<26/30定义认知障碍,63%存在认知障碍。
  • 使用经验证问卷(OAB-q SF、IIQ-SF、UDI、PGI-I)及新型问卷评估基线功能状态与技术舒适度/使用情况。

主要发现

  • CI组与非CI组基线OAB症状严重程度及影响的患者报告指标无统计学差异。
  • CI组基线技术使用与信心较低。
  • 1个月随访时CI组SNM控制器适当使用率较低,但患者报告结局无差异。

关键数值与推荐

  • 认知障碍定义:蒙特利尔认知评估<26/30。
  • 测试阶段成功定义:基线症状改善>50%。

临床怎么用

  • 对老年OAB拟行SNM者应筛查认知障碍,因其发生率高。
  • 认知障碍不应作为SNM测试阶段的排除因素,因测试成功率与短期患者报告结局不受影响。
  • 对认知障碍患者需关注设备使用培训与支持,因控制器适当使用率较低。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: We evaluated the impact of cognitive impairment (CI) on sacral neuromodulation (SNM) outcomes in older patients, including progression to full implant, patient-reported outcome measures, and device utilization. MATERIALS AND METHODS: This prospective trial recruited patients age ≥ 60 years scheduled for test-phase SNM for refractory overactive bladder (OAB). Screening for CI was completed and defined as Montreal Cognitive Assessment scores < 26/30.Patients underwent initial and follow-up assessments using validated questionnaires (Overactive Bladder Questionnaire, Short Form; Incontinence Impact Questionnaire, Short Form; Urinary Distress Inventory; Patient Global Impression of Improvement). Baseline functional status and technology comfort/use were assessed by novel questionnaire. The primary outcome of test-phase success (>50% improvement in baseline symptoms) was compared based on the presence of CI. Secondary outcomes included urinary questionnaire scores and device utilization. RESULTS: Of 92 patients recruited, 88 underwent test-phase SNM (mean age 73 ± 8 years, 89% female), and 63% had CI (Montreal Cognitive Assessment <26). Baseline patient-reported measures of OAB symptom severity and impact were not statistically different between groups. Patients with CI had lower baseline technology use and confidence. Overall test-phase success was 89% and did not differ based on CI (91% vs 87%, P = .7). At 1-month follow-up, patients with CI demonstrated lower rates of appropriate SNM controller use; however, patient-reported outcomes did not differ. CONCLUSIONS: Older patients with OAB presenting for SNM have a high incidence of CI, which is associated with reduced comfort using technology. However, there was no evidence that CI affected SNM test-phase success or short-term patient-reported outcomes.

来源:J Urol,查看原文。版权归原作者所有。

引用

  1. Shenhar C, Goldman HB, Slopnick E, et al. Sacral Neuromodulation for Overactive Bladder in the Aging Population: Does Cognitive Impairment Impact Outcomes? A Prospective Clinical Trial. J Urol. 2025. PMID: 40736472. doi:10.1097/JU.0000000000004683

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。